Studies back Imatron's EBT (electron beam tomography) for heart conditions:
This article was originally published in Clinica
Latest results from a trial of Imatron's electron beam tomography (EBT) scanner have backed previous findings which showed that the device could help evaluate emergency room patients with acute chest pain. The EBT coronary artery scan produced a negative predictive value of 100%, according to the new 134-patient study, published in the August edition of the American Journal Of Cardiology. The new data corroborates a similar study published in the Annals of Emergency Medicine (January), which showed that based on a negative scan, 800,000 patients could be safely discharged from emergency rooms in the US, said San Francisco, California-based Imatron.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.